Literature DB >> 24400859

Effect of genotype on pulmonary hypertension risk in patients with thalassemia.

Nattiya Teawtrakul1, Phuangpaka Ungprasert, Burabha Pussadhamma, Patcharawadee Prayalaw, Supan Fucharoen, Arunee Jetsrisuparb, Saranya Pongudom, Chittima Sirijerachai, Kanchana Chansung, Chinadol Wanitpongpun, Suporn Chuncharunee.   

Abstract

INTRODUCTION: Pulmonary hypertension is one of the major complications in patients with non-transfusion-dependent thalassemia (NTDT). Patients with NTDT have distinct genetic subgroups. Therefore, the effects of different genotype groups on pulmonary hypertension risk in patients with NTDT were assessed.
METHODS: A cross-sectional study was conducted in patients with NTDT aged ≥ 10 yr old at Srinagarind University Hospital and Udonthani Hospital, Thailand. Pulmonary hypertension risk was defined as peak tricuspid regurgitation velocity > 2.9 m/s by trans-thoracic echocardiography. Clinical characteristics and laboratory data that literature has indicated as risk factors for pulmonary hypertension were collected. The effect of genotype group on pulmonary hypertension risk was evaluated by using multivariate logistic regression analysis.
RESULTS: Of 219 patients, pulmonary hypertension risk was found in 24 patients (10.96%). All patients were categorized into two groups according to genetic data that included: (i) β-thalassemia (139, 63.5%), (ii) α-thalassemia and combined α and β-thalassemia (80, 36.5%). Genotype groups were statistically and significantly associated with pulmonary hypertension risk based on the adjusted odds ratios after adjustment for other factors. Patients with β-thalassemia had a statistically significant higher risk for pulmonary hypertension risk (odds ratio = 9.47, P = 0.036) compared to patients with α-thalassemia and patients with combined α and β-thalassemia.
CONCLUSION: The genotype group is an independent risk factor for pulmonary hypertension in patients with NTDT. Echocardiography should be routinely recommended for all patients with β-thalassemia. Routine screening in patients with α-thalassemia and combined α and β-thalassemia, however, may not be necessary or should focus on the older population.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  genotype; pulmonary hypertension; thalassemia

Mesh:

Year:  2014        PMID: 24400859     DOI: 10.1111/ejh.12261

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  5 in total

1.  Iron overload in non-transfusion-dependent thalassemia: association with genotype and clinical risk factors.

Authors:  Adisak Tantiworawit; Pimlak Charoenkwan; Sasinee Hantrakool; Worawut Choeyprasert; Chate Sivasomboon; Torpong Sanguansermsri
Journal:  Int J Hematol       Date:  2016-04-06       Impact factor: 2.490

2.  Pulmonary hypertension in thalassemia: a call to action.

Authors:  John C Wood
Journal:  Blood       Date:  2022-03-31       Impact factor: 22.113

3.  Pulmonary hypertension in well-transfused thalassemia major patients.

Authors:  Antonella Meloni; Jon Detterich; Alessia Pepe; Paul Harmatz; Tom D Coates; John C Wood
Journal:  Blood Cells Mol Dis       Date:  2014-11-24       Impact factor: 3.039

Review 4.  Pulmonary hypertension associated with thalassemia syndromes.

Authors:  Dustin R Fraidenburg; Roberto F Machado
Journal:  Ann N Y Acad Sci       Date:  2016-03-23       Impact factor: 5.691

5.  Review of disease-related complications and management in adult patients with thalassemia: A multi-center study in Thailand.

Authors:  Suporn Chuncharunee; Nattiya Teawtrakul; Noppadol Siritanaratkul; Nonlawan Chueamuangphan
Journal:  PLoS One       Date:  2019-03-20       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.